Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time. The FDA approved capivasertib, sold as Truqap by AstraZeneca, on June 12, ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted treatment option after the FDA cleared capivasertib, sold as Truqap, for use ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...

The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) in patients with ...

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) ...

CAI, has introduced in-house PTEN immunohistochemistry testing. The launch follows FDA approval of a biomarker guided therapy ...

AstraZeneca’s TRUQAP ® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient ...

NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.

Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP® NeoGenomics, Inc. (NASDAQ: NEO), a leading provider ...